Citations

Clear

114 citation(s) found for "Scott, Michael".

Guidelines for Perioperative Care in Elective Colorectal Surgery: Enhanced Recovery After Surgery (ERAS ® ) Society Recommendations: 2018
Gustafsson, Ulf , Scott, Michael J. , Hübner, Martin , Demartines, Nicolas , Rockall, Timothy , Young‐Fadok, Tonia M., Soop, Mattias , Boer, Hans D. de , Chang, George J. , Keßler, Hermann, Whang, Edward E. , Fawcett, William , Carli, F. , Lobo, Dileep N. , Rollins, Katie E. , Balfour, Angie , Ljungqvist, Olle , Demartines, N , Lobo, D N , Hübner, Martin , Nygren, Jonas , Francis, Nader Kamal , Hill, Andrew Graham , Urman, Richard D , Fichera, A., Grass, Fabian , Baldini, G., Riedel, Bernhard

Mayo Clinic

World Journal of Surgery | November 13, 2018 | Volume: 43 | Issue: 3 | Pages: 659-695

10.1007/s00268-018-4844-y | PMID 30426190 Get It

Abstract Background This is the fourth updated Enhanced Recovery After Surgery (ERAS ® ) Society guideline presenting a consensus for optimal perioperative care in colorectal surgery and providing graded recommendations for each ERAS item within the ERAS ® protocol. Methods A wide database search on English literature publications was performed. Studies on each item within the protocol were selected with particular attention paid to meta‐analyses, randomised controlled trials and large prospective cohorts and examined, reviewed and graded according to Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system. Results All recommendations on ERAS ® protocol items are based on best available evidence; good‐quality trials; meta‐analyses of good‐quality trials; or large cohort studies. The level of evidence for the use of each item is presented accordingly. Conclusions The evidence base and recommendation for items within the multimodal perioperative care pathway are presented by the ERAS ® Society in this comprehensive consensus review.
Association Between Left Atrial Appendage Occlusion and Readmission for Thromboembolism Among Patients With Atrial Fibrillation Undergoing Concomitant Cardiac Surgery
Piccini, Jonathan P. , Wang, Tongrong, Malaisrie, S. Chris, Holmes, David R. , Suri, Rakesh M. , Mack, Michael J. , Badhwar, Vinay , Gaca, Jeffrey G., Chow, Shein‐Chung, Brennan, James M. , Malaisrie, S. Chris , Friedman, Daniel J , Zheng, Jiayin , Jacobs, Jeffrey P. , Peterson, Eric D.

Mayo Clinic

JAMA | January 23, 2018 | Volume: 319 | Issue: 4 | Pages: 365

10.1001/jama.2017.20125 | PMID 29362794 Get It

Standardized Definition of Structural Valve Degeneration for Surgical and Transcatheter Bioprosthetic Aortic Valves
Dvir, Danny , Bourguignon, Thierry , Rosenhek, Raphaël , Webb, John G. , Treede, Hendrik , Enriquez‐Sarano, Maurice , Feldman, Ted , Wijeysundera, Harindra C. , Topilsky, Yan , Aupart, Michel, Reardon, Michael J. , Szeto, Wilson Y. , Gammie, James S. , Yoganathan, Ajit P. , Arbel, Yaron , Borger, Michael A. , Simonato, Matheus , Reisman, Mark, Makkar, Raj , Abizaid, Alexandre , Dahle, Gry , Aldea, Gabriel S. , Leipsic, Jonathon , Pîbarot, Philippe , Moat, Neil, Mack, Michael J. , Leon, Martin B. , Topilsky, Yan , Sarano, Maurice E, Pibarot, Phillippe , Enriquez-Sarano, Maurice , Otto, Catherine M , Hahn, Rebecca T , Mackensen, G. Burkhard , Kornowski, Ran , McCabe, James M , Kappetein, A. Pieter , Topilsky, Yan , Reardon, Michael J , Abizaid, Alexandre

Mayo Clinic

Circulation | January 22, 2018 | Volume: 137 | Issue: 4 | Pages: 388-399

10.1161/circulationaha.117.030729 | PMID 29358344 Get It

Bioprostheses are prone to structural valve degeneration, resulting in limited long-term durability. A significant challenge when comparing the durability of different types of bioprostheses is the lack of a standardized terminology for the definition of a degenerated valve. This issue becomes especially important when we try to compare the degeneration rate of surgically inserted and transcatheter bioprosthetic valves. This document, by the VIVID (Valve-in-Valve International Data), proposes practical and standardized definitions of valve degeneration and provides recommendations for the timing of clinical and imaging follow-up assessments accordingly. Its goal is to improve the quality of research and clinical care for patients with deteriorated bioprostheses by providing objective and strict criteria that can be utilized in future clinical trials. We hope that the adoption of these criteria by both the cardiological and surgical communities will lead to improved comparability and interpretation of durability analyses.
Clinical Impact of Diabetes Mellitus on Outcomes After Transcatheter Aortic Valve Replacement
Abramowitz, Yigal, Vemulapalli, Sreekanth , Chakravarty, Tarun , Li, Zhuokai , Holmes, David R. , Wang, Alice , Cheng, Wen , Forrester, James S. , Smalling, Richard W. , Thourani, Vinod H. , Mack, Michael J. , Leon, Martin B. , Makkar, Raj , Douglas, Pamela S. , Matsouaka, Roland A, Smalling, Richard, Thourani, Vinod, Mack, Michael, Leon, Martin, Makkar, Raj R., Douglas, Pamela S , Kapadia, Samir , Matsouaka, Roland

Mayo Clinic

Circulation: Cardiovascular Interventions | November 14, 2017 | Volume: 10 | Issue: 11 | Pages: No page available

10.1161/circinterventions.117.005417 | PMID 29138245 Get It

Background— Diabetes mellitus (DM) adversely affects morbidity and mortality for cardiovascular diseases and procedures. Data evaluating the outcomes of transcatheter aortic valve replacement (TAVR) in diabetic patients are limited by small sample size and contradictory results. We aimed to establish the magnitude of risk and the incremental influence of insulin dependency by examining short- and long-term adverse outcomes according to DM status and therapy in the world’s largest TAVR registry. Methods and Results— We analyzed data from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. In-hospital mortality, 30-day mortality, and 1-year mortality after TAVR in patients with and without DM were evaluated using multivariate modeling. Among 47 643 patients treated with TAVR from November 2011 through September 2015 at 394 US hospitals, there were 17 849 (37.5%) patients with DM. Overall, 6600 of the diabetic patients were insulin treated (IT). Thirty-day mortality was 5.0% in patients with DM (6.1% in IT DM and 4.4% in non-IT DM; P <0.001) versus 5.9% in patients without DM ( P <0.001). Overall, 1-year mortality was 21.8% in patients with DM (24.8% in IT DM and 20.1% in non-IT DM; P <0.001) versus 21.2% in patients without DM ( P =0.274). In a multivariable model, DM was associated with increased 1-year mortality (hazard ratio, 1.30; 95% confidence interval, 1.13–1.49; P <0.001). Subgroup multivariable analysis showed stronger mortality association in IT diabetics (hazard ratio, 1.57; 95% confidence interval, 1.28–1.91; P <0.001) than in non-IT diabetics (hazard ratio, 1.17; 95% confidence interval, 1.00–1.38; P =0.052). Conclusions— Our data establish the magnitude of short- and long-term risk conferred by DM and the incremental risk conferred by insulin dependency in the performance of TAVR. Clinical Trial Registration— URL: https://www.clinicaltrials.gov . Unique identifier: NCT01737528.
Mimics of Malignancy in Abdominal Imaging: Multisystem Radiology
Hartung, Michael , Menias, Christine O. , Mellnick, Vincent M. , Lubner, Meghan G. , Pickhardt, Perry J. , Hartung, Michael P, Mellnick, Vincent

Mayo Clinic

RadioGraphics | November 13, 2017 | Volume: 37 | Issue: 7 | Pages: 2202-2203

10.1148/rg.2017170071 | PMID 29131766 Get It

Peripheral Artery Disease and Transcatheter Aortic Valve Replacement Outcomes
Fanaroff, Alexander C. , Manandhar, Pratik , Holmes, David R. , Harrison, J. Kevin , Thourani, Vinod H. , Mack, Michael J. , Sherwood, Matthew W. , Vemulapalli, Sreekanth , Douglas, Pamela S. , Hughes, G Chad, Jones, W Schuyler, Douglas, Pamela S , Cohen, David Jonathan , Hughes, George Chad , Jones, W. Schuyler , Fanaroff, Alexander C

Mayo Clinic

Circulation: Cardiovascular Interventions | October 17, 2017 | Volume: 10 | Issue: 10 | Pages: No page available

10.1161/circinterventions.117.005456 | PMID 29042398 Get It

Background— Peripheral artery disease (PAD) is associated with increased cardiovascular mortality, and PAD risk factors overlap with those for aortic stenosis. The prevalence and outcomes associated with PAD in a population undergoing transcatheter aortic valve replacement (TAVR) are unknown. Methods and Results— Using the Society of Thoracic Surgeons/Transcatheter Valve Therapy Registry linked to Medicare claims data, we identified patients ≥65 years old undergoing TAVR from 2011 to 2015. We calculated hazard ratios for 1-year adverse outcomes, including mortality, readmission, and bleeding, for patients with PAD compared with those without, adjusting for baseline characteristics and postprocedure medications. Analyses were performed separately by access site (transfemoral and nontransfemoral). Of 19 660 patients undergoing transfemoral TAVR, 4810 (24.5%) had PAD; 3730 (47.9%) of 7780 patients undergoing nontransfemoral TAVR had PAD. In both groups, patients with PAD were significantly more likely to have coronary and carotid artery diseases. At 1-year follow-up, patients with PAD undergoing TAVR via transfemoral access had a higher incidence of death (16.8% versus 14.4%; adjusted hazard ratio, 1.14; P =0.01), readmission (45.5% versus 42.1%; hazard ratio, 1.11; P <0.001), and bleeding (23.1% versus 19.7%; hazard ratio, 1.18; P <0.001) compared with patients without PAD. Patients with PAD undergoing TAVR via nontransfemoral access did not have significantly higher rates of 1-year mortality or readmission compared with patients without PAD. Conclusions— PAD is common among patients undergoing commercial TAVR via transfemoral and nontransfemoral access. Among patients undergoing transfemoral TAVR, PAD is associated with a higher incidence of 1-year adverse outcomes compared with absence of PAD. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT01737528.
Aortic Valve Bioprostheses
Holmes, David R. , Mack, Michael J.

Mayo Clinic

Circulation | May 1, 2017 | Volume: 135 | Issue: 18 | Pages: 1749-1756

10.1161/circulationaha.116.025429 | PMID 28461416 Get It

Leaflet immobility and valve thrombosis have been reported with both transcatheter and surgical aortic valve bioprostheses. The relationships between these abnormalities and their incidence, time course, clinical significance, predisposing factors, optimal imaging modality, and current therapeutic options remain uncertain but are rapidly evolving. Four-dimensional computerized tomographic imaging has been determined to have the highest sensitivity in studies evaluating leaflet immobility and valve thrombosis. Echocardiography is also used during surveillance, but it appears to be less sensitive. The definitive diagnosis of valve thrombosis is based on a combination of diagnostic 4-dimensional computerized tomographic imaging findings, resolution of imaging abnormalities, and elevated transcatheter gradients with anticoagulation or surgical or pathological confirmation. Uncertainty about the incidence and clinical significance of the findings is the basis of 2 US Food and Drug Administration–approved studies comparing transcatheter and surgical aortic valve replacement with a subset undergoing surveillance 4-dimensional computerized tomographic imaging. Given the expansion of transcatheter aortic valve procedures, including potentially lower-risk patients, the resolution of these uncertainties is critical.
Morbidity and Mortality Differences Between Hematopoietic Cell Transplantation Survivors and Other Cancer Survivors
Chow, Eric J. , Cushing‐Haugen, Kara L. , Khera, Nandita , Lee, Stephanie J. , Leisenring, Wendy M. , Mueller, Beth A. , Cheng, Guang‐Shing , Boeckh, Michael, Martin, Paul J. , Schwartz, Stephen M, Baker, K. Scott, Boeckh, Michael , Schwartz, Stephen Mark , Baker, Kevin Scott , Leisenring, Wendy , Chow, Eric J , Lee, Stephanie J

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 35 | Issue: 3 | Pages: 306-313

10.1200/jco.2016.68.8457 | PMID 27870568 Get It

Purpose To compare the risks of serious health outcomes among hematopoietic cell transplantation (HCT) survivors versus a matched population of patients with cancer who did not undergo HCT, where the primary difference may be exposure to HCT. Methods Two-year HCT survivors treated at a comprehensive cancer center from 1992 through 2009 who were Washington State residents (n = 1,792; 52% allogeneic and 90% hematologic malignancies) were frequency matched by demographic characteristics and underlying cancer diagnosis (as applicable) to non-HCT 2-year cancer survivors, using the state cancer registry (n = 5,455) and the general population (n = 16,340) using driver’s license files. Late outcomes for all three cohorts were ascertained from the state hospital discharge and death registries; subsequent cancers were ascertained from the state cancer registry. Results After median follow-up of 7.1 years, HCT survivors experienced significantly greater rates of hospitalization compared with matched non-HCT cancer survivors (280 v 173 episodes per 1,000 person-years, P < .001) and greater all-cause mortality (hazard ratio [HR], 1.1; 95% CI, 1.01 to 1.3). HCT survivors had more hospitalizations or death with infections (10-year cumulative incidence, 31% v 22%; HR, 1.4; 95% CI, 1.3 to 1.6) and respiratory complications (cumulative incidence, 27% v 20%; HR, 1.4; 95% CI, 1.2 to 1.5). Risks of digestive, skin, and musculoskeletal complications also were greater among HCT versus non-HCT cancer survivors. The two groups had similar risks of circulatory complications and second cancers. Both HCT and non-HCT cancer survivors had significantly greater 10-year cumulative incidences of all major organ-system outcomes versus the general population. Conclusion History of HCT was associated with late morbidity and mortality among cancer survivors. In particular, clinicians who care for HCT survivors should be aware of their high rates of late respiratory and infectious complications.
Educational intervention for improving the appropriateness of transthoracic echocardiograms ordered by pediatric cardiologists
Sachdeva, Ritu , Douglas, Pamela S. , McCracken, Courtney , Lopez, Leo , Stern, Kenan W.D. , Eidem, Benjamin W., Benavidez, Oscar J., Weiner, Rory B., Welch, Elizabeth , Campbell, Robert M. , Kelleman, Michael Scott , Lai, Wyman W. , Douglas, Pamela S

Mayo Clinic

Congenital Heart Disease | February 22, 2017 | Volume: 12 | Issue: 3 | Pages: 373-381

10.1111/chd.12455 | PMID 28225219 Get It

Application of pediatric appropriate use criteria for initial outpatient evaluation of syncope
Phelps, Heather M. , McCracken, Courtney , Benavidez, Oscar J., Campbell, Robert M. , Douglas, Pamela S. , Eidem, Benjamin W., Lopez, Leo , Stern, Kenan W.D. , Welch, Elizabeth , Sachdeva, Ritu , Kelleman, Michael Scott , Lai, Wyman W. , Douglas, Pamela S

Mayo Clinic

Echocardiography | February 8, 2017 | Volume: 34 | Issue: 3 | Pages: 441-445

10.1111/echo.13475 | PMID 28177138 Get It

BackgroundSyncope is a common reason for outpatient transthoracic echocardiography (TTE). We studied the applicability of pediatric appropriate use criteria (AUC) on initial outpatient evaluation of children (≤18 years) with syncope.MethodsData were obtained before (Phase I, April–September 2014) and after (Phase II, January‐April 2015) the release of the AUC document from six participating pediatric cardiology centers. Site investigators determined the indication for TTE and assigned appropriateness rating based on the AUC document: Appropriate (A), May Be Appropriate (M), Rarely Appropriate (R), or “unclassifiable” (U) if it did not fit any scenario in the AUC document.ResultsOf the total 4562 TTEs, 310 (6.8%) were performed for syncope: 174/2655 (6.6%) Phase I and 136/1907 (7.1%) Phase II, P=.44. Overall, 168 (50.5%) were for indications rated A, 63 (18.9%) for M, 79 (23.7%) for R, and 23 (6.9%) for U. Release of AUC did not change the appropriateness of TTEs [A=51.6% vs 49.0%, P=.63, R=20.2% vs 28.3%, P=.09]. Overall syncope‐related R indications formed 15.7% of R indications for all the echocardiograms performed in the entire Pediatric Appropriate Use (PAUSE) study (11.9% Phase I and 22.4% Phase II, P=.002). TTEs were normal in majority of the patients except 7 that had incidental findings.ConclusionsIn conclusion, syncope is a common reason for indications rated R and release of the AUC document did not improve appropriate utilization of TTE in syncope. Targeted educational interventions are needed to reduce unnecessary TTEs in children with syncope.